Evolving Practices in Immune-Related Adverse Event Management: Insights From the IMMUCARE Multidisciplinary Board

Author:

Varnier Romain123ORCID,Fontaine-Delaruelle Clara34,Freymond Nathalie34,Essongue Aurore3,Bouali Anissa35,Boschetti Gilles36,Lebosse Fanny37,Tartas Sophie13,Milley Sarah38,Cugnet-Anceau Christine39,Novel-Catin Etienne310,Joubert Bastien311ORCID,Massy Emmanuel312,Dalle Stéphane38,Maillet Denis1313ORCID

Affiliation:

1. Department of Medical Oncology, Hospices Civils de Lyon, Pierre-Bénite, France

2. Research on Healthcare Performance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France

3. ImmuCare (Immunology Cancer Research), Institut de Cancérologie des Hospices Civils de Lyon, Lyon, France

4. Department of Respiratory Medicine, Hospices Civils de Lyon, Pierre-Bénite, France

5. Department of Cardiology, Hospices Civils de Lyon, Pierre-Bénite, France

6. Department of Gastroenterology, Hospices Civils de Lyon, Pierre-Bénite, France

7. Department of Hepatology, Lyon Liver Institute, Hospices Civils de Lyon, Lyon, France

8. Department of Dermatology, Hospices Civils de Lyon, Pierre-Bénite, France

9. Department of Endocrinology, Hospices Civils de Lyon, Pierre-Bénite, France

10. Department of Nephrology, Hospices Civils de Lyon, Pierre-Bénite, France

11. Department of Neuro-Oncology, Hospices Civils de Lyon, Bron, France

12. Department of Rheumatology, Hospices Civils de Lyon, Pierre-Bénite, France

13. Faculté de médecine Jacques Lisfranc, Saint-Etienne, France

Abstract

PURPOSE The management of immune-related adverse events (irAEs) requires multidisciplinary boards to handle complex cases. This study aimed to examine the evolving practices of the IMMUCARE board and to evaluate its impact on clinical practices. MATERIALS AND METHODS The IMMUCARE board gathers oncologists and organ specialists from the Cancerology Institute of the Lyon University Hospital since 2018. We conducted a retrospective analysis of its activity (participants' specialty, referred cases, and recommendations) from 2018 to 2021, coupled with a survey among the physicians who participated. RESULTS Across 68 board meetings, 245 cases from 195 patients were discussed. Each board had a median of six participants (IQR, 5-8). Participation rates varied across specialties and also over time (participation of nephrologists and rheumatologists significantly increased over time, whereas it decreased for endocrinologists). Most of the referred patients (89%) were treated at our center. Only 4% of referrals concerned eligibility for immune checkpoint inhibitor (ICI), whereas the majority pertained to irAEs. The board recommended ICI interruption for 56% and steroids for 41% of them. Immunosuppressants were recommended in 17% of cases, with a notable increase over time. ICI reintroduction was debated in 50% of cases, and the board identified a definitive contraindication in 26% of them. The survey of 49 of 98 physicians showed that the board significantly affected immunosuppressant introduction and ICI rechallenge decisions. The board's educational and collaborative benefits were highlighted, but time constraints posed challenges. CONCLUSION Our 4-year analysis of irAE management practices reveals changing patterns in the distribution of cases presented and in specialists' involvement. Dedicated multidisciplinary boards remain essential, particularly for intricate cases. Expanding access to these boards is crucial to ensure comprehensive care for all patients.

Publisher

American Society of Clinical Oncology (ASCO)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3